Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
100%(5 trials)

Phase Distribution

Ph phase_1
1
20%
Ph phase_2
4
80%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 24 (80.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia

NCT02595528
completedphase_2

A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia

NCT02780115
completedphase_2

AGN-199201 for the Treatment of Erythema With Rosacea

NCT01735201
completedphase_1

Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea

NCT01579084
completedphase_2

Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia

NCT02197806

Clinical Trials (5)

Showing 5 of 5 trials
NCT02595528Phase 2

A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia

Completed
NCT02780115Phase 2

A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia

Completed
NCT01735201Phase 2

AGN-199201 for the Treatment of Erythema With Rosacea

Completed
NCT01579084Phase 1

Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea

Completed
NCT02197806Phase 2

Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5